secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000886163-24-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand reports Q1 revenue $31M; net income $86.1M on Viking gain; reaffirms guidance; $100M Agenus royalty deal
--------------------------------------------------------------------------------

- Q1 total revenue $31.0M vs $44.0M last year; royalties up $19.1M from $17.6M.
- Net income $86.1M ($4.75 diluted) vs $43.6M, includes $60M realized gain on Viking stock.
- Core adjusted EPS $1.20 vs $1.33; decrease due to prior-year $15.3M Travere milestone.
- Reaffirms 2024 guidance: total revenue $130-142M, core adjusted EPS $4.25-4.75.
- Entered $100M royalty financing with Agenus for six partnered oncology programs; $75M upfront.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/0000886163-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/lgnd-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer